Syndrome Of Inappropriate Vasopressin Secretion — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for syndrome of inappropriate vasopressin secretion. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

Originators in Syndrome Of Inappropriate Vasopressin Secretion

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating syndrome of inappropriate vasopressin secretion. Each bar = one year. Y-axis scaled to peak year (8 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Syndrome Of Inappropriate Vasopressin Secretion — full disease profile
• AI Patent Landscape Report — type "syndrome of inappropriate vasopressin secretion" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner